Pharmacokinetics of standard versus high-dose isoniazid for treatment of multidrug-resistant tuberculosis.

ABSTRACT:

Background

The WHO-endorsed shorter-course regimen for MDR-TB includes high-dose isoniazid. The pharmacokinetics of high-dose isoniazid within MDR-TB regimens has not been well described.

Objectives

To characterize isoniazid pharmacokinetics at 5-15 mg/kg as monotherapy or as part of the MDR-TB treatment regimen.

Methods

We used non-linear mixed-effects modelling to evaluate the combined data from INHindsight, a 7 day early bactericidal activity study with isoniazid monotherapy, and PODRtb, an observational study of patients on MDR-TB treatment including terizidone, pyrazinamide, moxifloxacin, kanamycin, ethionamide and/or isoniazid.

Results

A total of 58 and 103 participants from the INHindsight and PODRtb studies, respectively, were included in the analysis.

SUBMITTER: Gausi K 

PROVIDER: S-EPMC10146925 | biostudies-literature | 2022 Aug

REPOSITORIES: biostudies-literature